Press Releases 2022 Archives - Biocon Biologics

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Global HQ

Press Releases 2022

Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’

Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%

Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022

Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine

Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan

Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%

University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre

Agree >>

Agree >>

Agree >>